TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the receiver operating characteristic curve for predicting difficult laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hippocampal stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hippocampal damping ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain Intensity Score at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse childhood experiences (ACEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Non-urothelial tract recurrence free survival (NUTRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Gene expression analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectus femoral thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Perceived effort
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Measurement of maximum respiratory pressures (MIP and PEM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in clinician-administered anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in parent reported anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in child reported anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies and magnitudes of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequencies and magnitudes of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequencies and magnitudes of liver toxicity (ALT flare-ups)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flynn's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour Mean Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Buccal and lingual bone socket dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sussex-Oxford Compassion for the Self Scale (SOCS-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 10-item Perceived-Stress Scale (PSS-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nasolabial fold length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle severity rating scale (WSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coma Recovery Scale-r (CRS-r)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants Who Achieved Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute post-surgical complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cervical Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significantly different metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Significantly different proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Plan to Receive a COVID-19 Vaccine Post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients achieving favorable outcomes (mRS 0-3) at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global home evaluations' attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Opioid consumption at 48 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative pain scores at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption at 72 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fall risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skills capacities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diaphragm and lung motion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary blood flow assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phase 1 Dose of HB-201 and HB-201/202 Combined with Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep Response Rate of Participants Treated with HB-201 or HB-201/202 Combined with Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle strength of the rectus femoris muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of bleeding management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Pain threshold level (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First episode of endothelial graft rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Blood viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 3-year progress free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary function test parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Learning Climate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Student Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of anti-TBEV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Factual knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of bladder weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Generalized Anxiety Disorder Assessment 7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WHO Disability Assessment Schedule (WHODAS 2.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Airway cross sectional diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airflow data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Upper airway pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severe Bronchopulmonary Dysplasia (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success of prefabricated Zirconia-based primary anterior crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in acetylated SOD2 and LCAD in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: complications of the block
Endpoint domain: Adverse events/effects
Primary endpoint: Change in interference in general activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in carotid artery unstable plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants with resolving vs non-resolving disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from enrollment in Immunoglobulin G (g/L) at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from enrollment in fatigue at 5 years
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Infant Toddler Quality of Life Questionnaire (ITQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain intensity at movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(w2-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Self-Control Cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fMRI BOLD Signal During Self-Control Decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pillar Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of SSB
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of SSB
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of dCBT-I intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of dCBT-I intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Poor neurological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Completed Colorectal Cancer Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Made a High Quality Decision Using the Multi-dimensional Measure of Informed Consent (MMIC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sufficient phenotypic and/or genomic data for therapeutic protocol assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of completed annual LCS in patients with a negative baseline screen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of completed recommended diagnostic follow-up scans or procedures in patients with a positive baseline screen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decline of PERC-15 (15th percentile)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recommended Phase 2 dose (RP2D) of NC410
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity of kidney dysfunction biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in muscular strength of leg extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Wear time of post-operative dressings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in level of reduced glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Assessment of Cancer Therapy - Head & Neck (FACT-H&N)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Alaryngeal Voice Handicap Index (AVHI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Experience of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak plantar strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent completing treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Change in Liver Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequacy of oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: COPD Exacerbation events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of NGS biomarker testing attempts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ICP difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Egg or peanut sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pulmonary vascular resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Life's Essential 8 (LE8) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak popliteal vein velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Daily infant dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative infant dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sites with reduced probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of serologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with arrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with redo ablation
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability of BPH 3-item questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Internal consistency of BPH 3-item questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Test-retest reliability of BPH 3-item questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Convergent validity of BPH 3-item questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need-based quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of conjunctival graft displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiation exposure Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure Operator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of In-Person Sessions Attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Days of At-Home Practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recommended phase 2 dose of the study drug combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Brief Pain Inventory (BPI) Interference scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on score of PCL-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression severity (PHQ9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety severity (GAD7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General psychological distress (HADSA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of propofol-related euphoria
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of propofol-related euphoria
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of propofol-related euphoria
Endpoint domain: Adverse events/effects
Primary endpoint: Concentrations of Protein Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration vs. time curve (AUC) without esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration (Cmax) without esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration vs. time curve (AUC) with esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration (Cmax) with esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Diagnosed with de novo AML or R/R B-cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of cancer survivor syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ex vivo muscle mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palpitation with Heyisheng Type Symptoms Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma Detection Rate of the right-sided colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: The boston bowel preparation scale of the right-sided colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Laryngeal air column width ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-surgical pain after the disappearance of the motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of global impairment of HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change from baseline total number of cWMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline total time of cTOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline score of BAI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of intraoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in uACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Neurodegenerative disease panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive Oxygen species (ROS) production of Leucocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood leukocyte phagocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastric volume (fasting and postprandial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric emptying profile (4 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Digital Addiction Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of AI-DSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of AI-DSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of AI-DSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermediate binocular uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Hypermethioninemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypomethioninemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Residual pancreatic stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interleukin-1b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Syndecan-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: awakening index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Total Pain Intensity Difference within 48 Hours (SPID-48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ureteral Stent Symptom Questionnaire (USSQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ultrasound status of the ductus arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Tolbutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Profile (AUCinf) of Tolbutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative percentage change in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days for serum bilirubin to decrease below phototherapy range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nurse elapsed time to respond to SpO2 alarm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes